Study Evaluation LXR-623 in Healthy Adults

NCT00379860 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2007-03-09

No results posted yet for this study

Summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Conditions

  • Healthy Subjects

Interventions

DRUG

LXR-623

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2007-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00379860 on ClinicalTrials.gov